

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Factors Associated with Having COVID-19 Among Pregnant and Non-Pregnant Women in Metro Manila, Philippines: A Multi-Center Longitudinal Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-070688
Article Type:	Original research
Date Submitted by the Author:	10-Dec-2022
Complete List of Authors:	<p>Llamas-Clark, Erlidia; University of the Philippines Manila, Heralde, Francisco M.; University of the Philippines Manila College of Medicine, Department of Molecular Biology and Biochemistry Lumandas, Mayan U.; Research Institute for Tropical Medicine, Department of Virology</p> <p>Cagayan, Maria Stephanie Fay; University of the Philippines Manila College of Medicine, Department of Pharmacology and Toxicology Villanueva-Uy, Maria Esterlita T.; University of the Philippines Manila, Institute of Child Health and Human Development, National Institutes of Health</p> <p>Chavez-Coloma, Leilani; Jose R Reyes Memorial Medical Center Valencia, Eleyne; Jose R Reyes Memorial Medical Center Cabana, Charizze Anne; Jose R Reyes Memorial Medical Center Espinosa, Lea Bernadette; Jose R Reyes Memorial Medical Center Anzures, Cynthia; Dr Jose Fabella Memorial Hospital, Department of Obstetrics and Gynecology</p> <p>Andal, Maria Lu; Dr Jose Fabella Memorial Hospital Martin, Carolina Paula; Ospital ng Maynila Medical Center Suarez, Patricia Nevira; Ospital ng Maynila Medical Center Quanico, Celine; Ospital ng Maynila Medical Center Beltran, Julia; Ospital ng Maynila Medical Center de Guzman, Vanessa; Justice Jose Abad Santos General Hospital Capitulo, Ryan; Justice Jose Abad Santos General Hospital Dominguez, Arlene; Sta. Ana Hospital</p> <p>Recio, Abygail; Sta. Ana Hospital Feliciano, Jeremiah; University of the Philippines Manila College of Medicine</p> <p>Baja, Emmanuel; University of the Philippines Manila, Exposure Assessment, Epidemiology, and Risk Lab Institute of Clinical Epidemiology; University of the Philippines Manila, Department of Clinical Epidemiology</p> <p>Rosell-Ubial, Paulyn Jean; University of the Philippines Manila College of Public Health</p>
Keywords:	COVID-19, EPIDEMIOLOGIC STUDIES, Public health < INFECTIOUS DISEASES, OBSTETRICS

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# Factors Associated with Having COVID-19 Among Pregnant and Non-Pregnant Women in Metro Manila, Philippines: A Multi-Center Longitudinal Cohort Study

Erlidia F. Llamas-Clark, MD, PhD<sup>1-5</sup>, Francisco M. Heralde III, MSc, PhD<sup>2</sup>, Mayan U. Lumandas, MD, MSc<sup>3</sup>, Maria Stephanie Fay S. Cagayan, MD, PhD<sup>4</sup>, Maria Esterlita T. Villanueva-Uy, MD, MPH<sup>5</sup>, Leilani C. Chavez-Coloma, MD<sup>6</sup>, Eleyne I. Valencia, MD<sup>6</sup>, Charizze Anne S. Cabana, MD<sup>6</sup>, Lea Bernadette H. Espinosa, MD<sup>6</sup>, Cynthia U. Anzures, MD<sup>7</sup>, Maria Lu D. Andal, MD<sup>7</sup>, Carolina Paula C. Martin, MD<sup>8</sup>, Patricia Nevira V. Suarez, MD<sup>8</sup>, Celine D. Quanico, MD<sup>8</sup>, Julia B. Beltran, MD<sup>8</sup>, Vanessa D. de Guzman, MD<sup>9</sup>, Ryan B. Capitulo, MD<sup>9</sup>, Arlene R. Dominguez, MD<sup>10</sup>, Abygail L. Recio, MD<sup>10</sup>, Jeremiah F. Feliciano, BSc<sup>11</sup>, Emmanuel S. Baja, MSc, ScD<sup>12</sup>, Pauly Jean B. Rosell-Ubial, MD, MPH<sup>13</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, College of Medicine, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>2</sup>Department of Molecular Biology and Biochemistry, College of Medicine, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>3</sup>Department of Virology, Research Institute for Tropical Medicine, Muntinlupa City, 1781 Philippines

<sup>4</sup>Department of Pharmacology and Toxicology, College of Medicine, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>5</sup>Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>6</sup>Jose R. Reyes Memorial Medical Center, Rizal Ave, Santa Cruz, City of Manila, 1000 Philippines

<sup>7</sup>Dr. Jose Fabella Memorial Hospital, Lope de Vega St, Santa Cruz, City of Manila, 1003 Philippines

<sup>8</sup>Hospital ng Maynila Medical Center, 719 Quirino Avenue, corner Roxas Blvd, Malate, City of Manila, 1004 Philippines

<sup>9</sup>Justice Jose Abad Santos General Hospital, Numancia St, Binondo, City of Manila, 1008 Philippines

<sup>10</sup>Sta. Ana Hospital, New Panaderos Ext, Santa Ana, City of Manila, 1009 Philippines

<sup>11</sup>College of Medicine, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>12</sup>Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>13</sup>College of Public Health, University of the Philippines Manila, City of Manila, 1000 Philippines

Corresponding and Primary author:

Erlidia F. Llamas-Clark, MD, PhD | [efllamasclark@up.edu.ph](mailto:efllamasclark@up.edu.ph); +63 9399148195

**WORD COUNT:** 1938 words

## ABSTRACT

**Objective.** To determine potential risk factors associated with having COVID-19 among unvaccinated pregnant and non-pregnant women.

**Design.** A multicenter prospective cohort study among eligible women in Metro Manila, Philippines, from 2020 to 2022.

**Setting.** Five national and local hospital research sites altogether recruited and screened 500 consenting eligible individuals.

**Participants.** Pregnant and non-pregnant participants meeting the eligibility criteria were admitted for an RT-PCR determination of SARS-CoV-2, pregnancy testing and ultrasound, and an interview with an administered questionnaire.

**Exposures.** Primary exposure was pregnancy; secondary exposures involve sociodemographic, lifestyle, and obstetric-gynecologic factors.

**Outcome measure.** Outcome being measured was COVID-19 status.

**Results.** Pregnancy was found to be a significant risk factor (PR=1.184, 95CI[1.096,1.279]), as was being a white-collar worker (PR=1.123, 95CI[1.02,1.235]), traveling outside the country (PR=1.369, 95CI[1.083, 1.173]), and being infected by at least one vaccine-preventable disease (VPD) (PR=1.208, 95CI[1.113,1.310]). Protective factors included having graduate-level education (PR=0.787, 95CI[0.649,0.954]), immunization against a VPD (PR=0.795, 95CI[0.733,0.862]), and practicing contraception (PR=0.889, 95CI[0.824,0.960]).

**Conclusion.** This study is the first in the country to determine the risks influencing COVID-19 infection among unvaccinated pregnant and non-pregnant women. Pregnancy is a significant risk for the disease among women in Metro Manila, and other risk and protective factors may be said to lie along socioeconomic lines. Further studies are needed to elucidate the development of the disease in pregnant women, and the maternal and neonatal effects of COVID-19 via potential vertical mechanisms of transmission.

**KEYWORDS** COVID-19, Pregnancy, Prospective studies, Risk factors

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- This article provides the first multi-center determination study in public hospitals in the Philippines to serve as a baseline for the determination of risk factors of COVID-19 in women.
- This article also incorporates in the analysis, some of the pre-existing conditions and pressures experienced by Filipino women as a driving force behind COVID-19 risk.

- Further studies with an emphasis on the longitudinal nature of the disease throughout the gestation period are recommended to determine the differential progression of the disease in terms of changes brought about by pregnancy.
- Research on clinical manifestations, progression, and outcomes of COVID-19 among women is recommended.

## INTRODUCTION

**Background.** The rapid transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused cases of Coronavirus Disease 2019 (COVID-19) to rise in many countries since it was first reported in Wuhan, China, in December 2019<sup>1</sup>. By the time the WHO declared it a pandemic, significant repercussions were already observed in worldwide social and economic life<sup>2</sup>. The multifaceted nature of this pandemic gives rise to concerns about identifying relevant risk factors, especially for vulnerable populations. Men have higher mortality risks when infected, but women may have higher risks of worse health outcomes and less healthcare access due to pre-existing socioeconomic gaps exacerbated by the pandemic<sup>3,4</sup>. At par or possibly greater risks are pregnant women and their unborn; both susceptible to infection due to their weakened immune system<sup>5</sup>. Evidence of sex- and pregnancy-based differences in COVID-19 vulnerability indicate a need to determine the relevant socio-demographic, lifestyle, and obstetric-gynecologic risk factors. This is especially urgent in countries whose pandemic response policies prioritize universal community health over the needs of vulnerable populations like women because of scarce resources.

**Objective.** To our knowledge, there is scant local literature describing the risk factors of COVID-19 among unvaccinated women in the Philippines during the pandemic. Furthermore, studies on the matter are yet to incorporate the intersectionality of pre-existing socioeconomic pressures on women which may compound the risk determination for the disease. In conducting this research, we provided baseline information and comparison between pregnant and non-pregnant populations in this pandemic and validated the findings of relevant literature while offering new and local insights into the characteristics of unvaccinated women admitted to public hospitals in a highly populous and heterogenous city. This study thus aimed to identify the risk factors associated with COVID-19 in unvaccinated pregnant and non-pregnant women in five hospitals in the City of Manila, Philippines.

## METHODS

1  
2  
3       **Study design and setting.** This prospective multicenter cohort study is part of a  
4 comprehensive protocol to determine the risk factors, clinical manifestations, progression, and  
5 maternal-neonatal outcomes of COVID-19 vertical transmission among pregnant and non-  
6 pregnant women in Metro Manila<sup>6</sup>. Specific details on the procedures such as detailed  
7 eligibility criteria, data sources, handling of bias, missing data, and non-response, and  
8 sensitivity analyses can be found in said protocol. Cases were recruited from the study  
9 population consisting of all pregnant or non-pregnant women who will consult among the five  
10 public hospital research sites under the Department of Health (DOH) or the Manila City  
11 Government, ranging from November 30, 2020, to March 31, 2022. The Research Institute of  
12 Tropical Medicine (RITM) processed the collected samples using reverse-transcription PCR  
13 for diagnosis and analyses of unconventional samples. All study participants meeting the  
14 inclusion criteria were admitted to the study following a thorough briefing and with their  
15 written and continuing consent.

16  
17       **Patient and public involvement.** Patients and(or) the public were not involved in the  
18 design. All participants were recruited with informed and continuing consent from research  
19 hospital sites.

20  
21       **Data collection.** Laboratory determination of SARS-CoV-2 and pregnancy status were  
22 carried out after collection of samples from the participants. They were also given a validated  
23 self-administered structured COVID-19 infection in adults questionnaire adapted from the New  
24 South Wales Department of Health<sup>6</sup>. The questionnaire will profile the socio-demographic,  
25 lifestyle, obstetric-gynecologic, medical history, and pregnancy-related characteristics of each  
26 participant.

27  
28       **Outcome and exposures.** Outcome measurement was COVID-19 status, which is  
29 confirmed from the RT-PCR test. Primary exposure was pregnancy status, determined from  
30 pregnancy test and(or) ultrasound. Secondary exposures were socio-demographic, lifestyle,  
31 and obstetric-gynecologic factors, as will be discussed in later sections.

32  
33       **Statistical analysis.** Descriptive statistics profiled the socio-demographic, lifestyle,  
34 and obstetric-gynecologic characteristics of pregnant and non-pregnant cohorts. The crude  
35 prevalence ratio (cPR) and the corresponding 95% confidence interval (95CI) were calculated  
36 after regressing a bivariable generalized linear model using a Poisson distribution with robust  
37 variance correction and a log link function between the characteristics as predictors, and  
38 COVID-19 status as the outcome. This model was used as the best option to minimize the  
39 overestimation of the true prevalence ratio among other alternatives<sup>7</sup>. The same regression  
40 model was used to create adjusted prevalence ratios (aPRs) and to determine which among the



characteristics are better risk indicators of COVID-19 susceptibility among the women in the study.

## RESULTS

Five hundred respondents were included from the five hospitals throughout the study period. Of them, 233 (46.6%) were COVID-19-positive and 267 (53.5) were pregnant. After omitting missing observations in the variables of interest, only 352 (70.4%) cases remained for regression analyses and calculation of prevalence ratios. Most participants were lost to follow-up, particularly during delivery, when most of them preferred to deliver out of the hospital research sites. **Table 1** shows the socio-demographic and lifestyle characteristics of the respondents.

**Table 1.** Characteristics of respondents included in the present study, stratified by pregnancy status.

Characteristics	Total, n=500	Non- pregnant, n=233	Pregnant, n=267
<b>SOCIODEMOGRAPHIC FACTORS</b>			
<i>Admitting hospital</i>			
DJFMH	166 (33.2)	78 (15.6)	88 (17.6)
JRRMMC	168 (33.6)	78 (15.6)	90 (18.0)
OMMC	58 (11.6)	26 (5.2)	32 (6.4)
SAH	59 (11.8)	29 (5.8)	30 (6.0)
JJASGH	49 (9.8)	22 (4.4)	27 (5.4)
<i>Age</i>			
18-30	246 (49.2)	77 (15.4)	169 (33.8)
31-48	202 (40.4)	105 (21.0)	97 (19.4)
>49	52 (10.4)	51 (10.2)	1 (0.2)
<i>Resides in Manila</i>			
No	226 (45.7)	89 (17.9)	137 (27.7)
Yes	269 (54.3)	139 (28.1)	130 (26.3)
Missing	5	5	0
<i>Address type</i>			
Household	494 (98.9)	228 (45.7)	266 (53.3)
Aged care facility	1 (0.2)	1 (0.2)	0 (0.0)
Other residence type	4 (0.8)	3 (0.6)	1 (0.2)
Missing	1	1	0
<i>Educational attainment</i>			
Elementary	33 (6.6)	18 (3.6)	15 (3.0)
High school	234 (46.8)	100 (20.0)	134 (26.8)
College	195 (39.0)	85 (17.0)	110 (22.0)
Graduate school	35 (7.0)	30 (6.0)	5 (1.0)
Vocational	3 (0.6)	0 (0.0)	3 (0.6)
<i>Type of occupation</i>			
Unemployed/Unstable	306 (64.3)	116 (24.4)	190 (39.9)
Blue-collar job	42 (8.8)	25 (5.3)	17 (3.6)
White-collar job	128 (26.9)	87 (18.3)	41 (8.6)
Missing	24	5	19
<i>Marital status</i>			
Single	278 (55.6)	103 (20.6)	175 (35.0)

Married	189 (37.8)	109 (21.8)	80 (16.0)
Cohabiting	27 (5.4)	15 (3.0)	12 (2.4)
Widowed	6 (1.2)	6 (1.2)	0 (0.0)
<b>Religion</b>			
Catholic	440 (89.8)	196 (40.0)	244 (49.8)
Protestant	11 (2.2)	8 (1.6)	3 (0.6)
Muslim	15 (3.1)	9 (1.8)	6 (1.2)
Others	24 (4.9)	13 (2.7)	11 (2.2)
Missing	10	7	3
<b>Socioeconomic status</b>			
Less than Php5,000	250 (50.3)	96 (19.3)	154 (30.9)
Php5,001 to Php20,000	159 (31.9)	71 (14.3)	88 (17.7)
Php20,001 and above	88 (17.7)	64 (12.9)	23 (4.8)
Missing	3	2	1
<b>LIFESTYLE FACTORS</b>			
<b>Use of contraceptive</b>			
No	338 (77.6)	168 (33.6)	220 (44.0)
Yes	112 (22.4)	65 (13.0)	47 (9.4)
<b>Smoking history</b>			
Never smoker	468 (93.8)	207 (41.5)	261 (52.3)
Ever smoker	31 (6.2)	25 (5.0)	6 (1.2)
Missing	1	1	0
<b>Alcohol use</b>			
Never alcoholic	412 (82.6)	170 (34.1)	242 (48.5)
Ever alcoholic	87 (17.4)	62 (12.4)	25 (5.0)
Missing	1	1	0
<b>Illicit drug use</b>			
No	496 (99.4)	230 (46.1)	266 (53.3)
Yes	3 (0.6)	2 (0.4)	1 (0.2)
Missing	1	1	0
<b>Immunized from at least one VPD</b>			
No	260 (64.4)	106 (26.2)	154 (38.1)
Yes	144 (35.6)	37 (9.2)	107 (26.5)
Missing	96	90	6
<b>History of at least one VPD</b>			
No	344 (69.8)	160 (32.5)	184 (37.3)
Yes	149 (30.2)	68 (13.8)	81 (16.4)
Missing	7	5	2
<b>Blood type</b>			
A	113 (24.1)	43 (9.2)	70 (14.9)
B	88 (18.8)	37 (7.9)	51 (10.9)
O	237 (50.5)	113 (24.1)	124 (26.4)
AB	31 (6.6)	15 (3.2)	16 (3.4)
Unrecalled	31	25	6
<b>Travel history</b>			
No	484 (96.8)	219 (43.8)	265 (53.0)
Yes	16 (3.2)	14 (2.8)	2 (0.4)
<b>OBSTETRIC-GYNECOLOGIC FACTORS</b>			
<b>Gravidity</b>			
Two at most	320 (64.1)	153 (30.7)	167 (33.5)
At least 3	179 (35.9)	79 (15.8)	100 (20.0)
Missing	1	1	0
<b>Parity</b>			
Two at most	376 (75.4)	161 (32.3)	215 (43.1)
At least 3	123 (24.6)	71 (14.2)	52 (10.4)
Missing	1	1	0
<b>COVID-19 EXPOSURE</b>			
Negative	267 (53.4)	120 (24.0)	147 (29.4)

Positive	233 (46.6)	113 (22.6)	120 (24.0)
----------	------------	------------	------------

\*Unless otherwise specified, all summary statistics are expressed in counts and percentage of the total, *n* (%).

Most respondents tested negative for COVID-19 during the study, which is also consistent for pregnant (29.4%) and nonpregnant (24.0%) cohorts. More than half of all respondents reside in Manila City and were admitted to DOH partner hospitals, which are among the highest-capacity tertiary institutions in the country. Furthermore, most respondents live in households, are Catholic, have never smoked nor drank alcoholic beverages, have not consumed illicit drugs, have an O blood type or have never left the country during the pandemic. Among pregnant respondents, the majority were younger, high school graduates, unemployed, single, making less than PHP5,000.00 (USD84.94) per month, not practicing contraception, have been infected or immunized against at least one vaccine-preventable disease (VPD), have been twice pregnant at most, or with up to two viable pregnancies.

**Table 2** shows crude and adjusted prevalence ratios for potential risk factors of COVID-19. Significant risk factors among unvaccinated women include being pregnant, white-collar worker, having been infected with at least one VPD, and leaving the country during the pandemic. Protective factors appear to be having graduate-level education, practicing contraception, and being immunized for at least one VPD. Blood type does not seem to be a significant predictor of COVID-19 among women, as well as gravidity, parity, smoking history, and alcohol use.

**Table 2.** Crude (cPR) and adjusted (aPR) prevalence ratios with 95% confidence intervals for associations between COVID-19 and covariates.

Characteristics	Total, n=352	COVID- 19- negative, n=220	COVID- 19- positive, n=132	cPR[95CI]	aPR[95CI]
<b>OBSTETRIC-GYNECOLOGIC FACTORS</b>					
<b>Pregnancy status</b>					
Non-pregnant	120 (34.1)	85 (24.1)	35 (9.9)	1.000	1.000
Pregnant	232 (65.9)	135 (38.4)	97 (27.6)	1.149 [1.063, 1.242]*	1.184[1.096, 1.279]*
<b>Gravidity</b>					
Two at most	225 (63.9)	142 (40.3)	83 (23.6)	1.000	1.000
At least 3	127 (36.1)	78 (22.2)	49 (13.9)	1.012 [0.938, 1.093]	1.075 [0.975, 1.185]
<b>Parity</b>					
Two at most	270 (76.7)	165 (46.9)	105 (29.8)	1.000	1.000
At least 3	82 (23.3)	55 (15.6)	27 (7.7)	0.957 [0.877, 1.044]	0.934 [0.842, 1.036]
<b>SOCIODEMOGRAPHIC FACTORS</b>					
<b>Age</b>					

18-30	189 (53.7)	118 (33.5)	71 (20.2)	1.000	1.000
31-48	140 (39.8)	87 (24.7)	53 (15.1)	1.002 [0.928, 1.082]	0.968 [0.896, 1.045]
>49	23 (6.5)	15 (4.3)	8 (2.3)	0.980 [0.841, 1.142]	0.999 [0.857, 1.163]
<b>Resides in Manila</b>					
No	175 (51.0)	128 (36.4)	48 (13.6)	1.000	1.000
Yes	168 (48.9)	92 (26.1)	84 (23.9)	1.161 [1.080, 1.247]*	1.055 [0.990, 1.123]
<b>Educational attainment</b>					
Elementary	16 (4.5)	9 (2.6)	7 (1.9)	1.000	1.000
High school	171 (48.6)	110 (31.3)	61 (17.3)	0.944 [0.791, 1.127]	0.917 [0.807, 1.043]
College	143 (40.6)	83 (23.6)	60 (17.0)	0.988 [0.826, 1.180]	0.927 [0.809, 1.063]
Post-graduate	19 (5.4)	16 (4.5)	3 (0.9)	0.805 [0.646, 1.004]	0.787 [0.649, 0.954]*
Vocational	3 (0.9)	2 (0.6)	1 (0.3)	0.928 [0.601, 1.432]	0.798 [0.62, 1.027]
<b>Type of occupation</b>					
Unemployed/Unstable	243 (69.0)	160 (45.5)	83 (23.6)	1.000	1.000
Blue-collar job	25 (7.1)	14 (3.9)	11 (3.1)	1.073 [0.931, 1.237]	1.02 [0.889, 1.169]
White-collar job	84 (23.9)	46 (13.1)	38 (10.8)	1.083 [0.994, 1.179]	1.123 [1.02, 1.235]*
<b>Marital status</b>					
Single	207 (58.8)	133 (37.8)	74 (21.0)	1.000	1.000
Married	126 (35.8)	73 (20.7)	53 (15.1)	1.047 [0.969, 1.131]	1.057 [0.979, 1.142]
Cohabiting	15 (4.3)	12 (3.4)	12 (0.9)	0.884 [0.742, 1.053]	0.906 [0.759, 1.082]
Widowed	4 (1.1)	2 (0.6)	2 (0.6)	1.105 [0.794, 1.537]	0.990 [0.610, 1.606]
<b>Religion</b>					
Catholic	324 (92.0)	202 (57.4)	122 (34.7)	1.000	1.000
Protestant	5 (1.4)	2 (0.6)	3 (0.9)	1.162 [0.886, 1.524]	1.193 [0.913, 1.558]
Muslim	9 (2.6)	6 (1.7)	3 (0.9)	0.969 [0.766, 1.224]	1.056 [0.896, 1.244]
Others	14 (3.9)	10 (2.8)	4 (1.1)	0.934 [0.774, 1.127]	0.982 [0.841, 1.147]
<b>Socioeconomic status</b>					
Less than Php5,000	198 (56.3)	136 (38.6)	62 (17.6)	1.000	1.000
Php5,001 to Php20,000	101 (28.7)	54 (15.3)	47 (13.4)	1.116 [1.027, 1.212]*	1.060 [0.985, 1.141]
Php20,001 and above	53 (15.1)	30 (8.5)	23 (6.5)	1.092 [0.983, 1.213]	1.048 [0.935, 1.174]
<b>LIFESTYLE FACTORS</b>					
<b>Using contraception</b>					
No	282 (80.1)	166 (47.2)	116 (32.9)	1.000	1.000
Yes	70 (19.9)	54 (15.3)	16 (4.5)	0.870 [0.796, 0.952]*	0.889 [0.824, 0.960]*
<b>Smoking history</b>					
Never smoker	337 (95.7)	209 (59.4)	128 (36.4)	1.000	1.000
Ever smoker	15 (4.3)	11 (3.1)	4 (1.1)	0.918 [0.766, 1.100]	1.124 [0.955, 1.324]
<b>Alcohol use</b>					
Never smoker	301 (85.5)	185 (52.6)	116 (32.9)	1.000	1.000
Ever smoker	51 (14.5)	35 (9.9)	16 (4.5)	0.948 [0.854, 1.053]	1.002 [0.909, 1.104]

<b><i>Immunized VPD &gt; 1</i></b>					
No	219 (62.2)	103 (29.3)	116 (32.9)	1.000	1.000
Yes	133 (37.8)	117 (33.2)	16 (4.4)	0.732 [0.686, 0.782]*	0.795 [0.733, 0.862]*
<b><i>History VPD &gt; 1</i></b>					
No	238 (67.6)	181 (51.4)	57 (16.2)	1.000	1.000
Yes	114 (32.4)	39 (11.1)	75 (21.3)	1.338 [1.249, 1.432]*	1.208 [1.113, 1.310]*
<b><i>Blood type</i></b>					
A	82 (23.3)	58 (16.5)	24 (6.8)	1.000	1.000
B	68 (19.3)	42 (11.9)	26 (7.4)	1.069 [0.955, 1.197]	1.047 [0.958, 1.146]
O	181 (51.4)	106 (30.1)	75 (21.3)	1.094 [0.998, 1.199]	1.028 [0.958, 1.103]
AB	21 (5.9)	14 (3.9)	7 (1.9)	1.031 [0.871, 1.222]	0.967 [0.837, 1.117]
<b><i>Travel history</i></b>					
No	349 (99.1)	220 (62.5)	129 (36.6)	1.000	1.000
Yes	3 (0.9)	0 (0.0)	3 (0.9)	1.460 [1.407, 1.515]*	1.369 [1.083, 1.173]*

\*Significant at 5% level of significance.

## DISCUSSION

This is the first multicenter study in the country to address relevant gaps in the literature by elucidating the systemic inequities and circumstances that contextualize the differential risks in sociodemographic, lifestyle, and obstetric-gynecologic factors between pregnant and non-pregnant women during the early pandemic when vaccines were still unavailable. Further research with consideration of the temporal interaction of the disease with pregnancy is suggested in view of the cumulative nature of this cohort study.

**What are the living conditions of pregnant women in the Philippines during the pandemic?** Pregnant women were more likely younger, single, unemployed or hold unstable jobs, or make lesser monthly income. Before the pandemic, there were already fewer women in the Philippine labor force in 2015<sup>8</sup>. Filipinas also had a higher incidence of vulnerable employment like self-employment and unpaid home duties, often associated with insufficient income and unsafe working conditions. Prevailing conservative gender roles also translate to women usually being housemakers, even as the Philippines ranks first in gender equality among Asian countries in 2022<sup>4,9</sup>. This cultural practice relegates women from the job market, causing insecure, lower-income employment with lesser bargaining power in most national economies<sup>4</sup>. Pregnancy ultimately compounds these intersecting inequities due to behavioral tendencies to take lesser risks even in decisions that may benefit their physical or financial wellbeing<sup>10,11</sup>.

### **How is COVID-19 risk different among women during the pandemic?**

Multivariable analysis found that COVID-19-positive women may more likely present as pregnant, white-collar workers, have had at least one VPD infection, or have traveled outside the country during the pandemic. Pregnancy, as a risk factor, supports other studies' findings which have variously been attributed to a more vulnerable immune constitution during gestation<sup>5</sup>. On the other hand, white-collar workers being at higher risk may be explained by the general nature of their occupations in healthcare, essential bureaucracy as part of a skeleton workforce, and similar jobs that result in increased interaction with suspect cases of the disease. For this reason, it is also rational, as other studies found to varying significance, to expect international travel as a risk factor for COVID-19 infection and its consequent spread<sup>12,13</sup>. Having a history of VPD infection as a risk is a novel finding that warrants further research. The researchers hypothesize that the social and environmental influences that led to a prior VPD infection may have been the same conditions that caused COVID-19 transmission, especially among the densely populated shanty towns of Manila City with poor sanitation systems and ventilation. In the same vein, immunization for at least one VPD appears to be protective against COVID-19, which likewise requires further immunologic and socio-behavioral investigations. Furthermore, graduate-level education also lowers infection risk, suggesting a positive effect of higher education in forming informed decisions among individuals. Subsequently, contraception also lowers the risk of COVID-19 presumably due to the positive health outcomes inherent in the behavior that could have translated into COVID-19-safe practices. Furthermore, some studies suggest that higher or physiologic estrogen levels, especially during consumption of combined hormonal contraceptives (CHCs) confer a humoral immune-reactive response by inducing higher antibody levels<sup>14,15</sup>.

### **CONCLUSION**

Pregnancy is a significant risk factor for COVID-19 infection among women, as is being a white-collar worker, being infected by at least one VPD, and traveling outside the country during the pandemic. On the other hand, protective factors include graduate-level education, practicing contraception, and being immunized for at least one VPD.

Our findings are useful in providing baseline findings on the characteristics that exacerbate and relieve the susceptibility of unvaccinated Filipinas to COVID-19. This will inform the development of public health response and vaccination efforts with consideration to vulnerable populations, including pregnant women. Further investigations as to the clinical

1  
2  
3 manifestations, maternal and neonatal outcomes, and the possibility of vertical transmission of  
4 COVID-19 are recommended.  
5  
6  
7

## 8 **COMPETING INTERESTS**

9  
10 The authors declare no potential conflicts of interest regarding the research, authorship,  
11 and publication of this article.  
12  
13  
14

## 15 **AUTHOR CONTRIBUTIONS**

16  
17 EL-C is the principal investigator and first author of this study who gave instrumental  
18 contributions to the concept, research design and methodology including the implementation  
19 and management of this study. FMH, ESB, METV-U, MSFC, MUL and PJR-U assisted in  
20 specific components of the study. LCC-C, EIV, HJDC, LBHE, CUA, MLDA, CPCM, PVS,  
21 JBB, VDG, RBC, ARD, and ALR implemented the research methodology and provided  
22 practical insights and discussion which were considered in the study. ESB, JFF and ELC  
23 conducted statistical data analyses and interpretation. JFF and EL-C drafted the article and  
24 visualization, and provided contextual interpretations into the study findings. All have critically  
25 revised and approved the final version of the manuscript.  
26  
27  
28  
29  
30  
31  
32  
33

## 34 **FUNDING**

35  
36 This study was made possible by grants from the Australian Awards and Alumni  
37 Engagement Program, Department of Science and Technology - Philippine Council for Health  
38 Research and Development (DOST-PCHRD), and the Philippine Obstetrical and  
39 Gynecological Society (POGS).  
40  
41  
42  
43  
44

## 45 **ACKNOWLEDGEMENTS**

46  
47 The authors would like to thank the following: Research Institute of Tropical  
48 Medicine—Dr Celia Carlos; Manila City Officials headed by former Mayor Francisco 'Isko  
49 Moreno' Domagoso; Office of the Mayor Honorable Honey Lacuna-Pangan, the Manila City  
50 Councilors headed by Councilor Joel Chua, and Manila City Health Department Staff—Dr  
51 Arnold Pangan, Dr Gina Pardilla, and Dr Rosalina R Tan and other public health staff. Our  
52 gratitude to the administrators, resident physicians and medical officers and staff of the project  
53 site hospitals including the research staff and all participants who contributed in this  
54 multicenter COVID19 and women study for the Philippines.  
55  
56  
57  
58  
59  
60

## PATIENT CONSENT FOR PUBLICATION

Obtained.

## DATA AVAILABILITY STATEMENT

Data are available upon reasonable request.

## ETHICS APPROVAL

The study was approved by the DOH Single Joint Research Ethics Board (DOH-SJREB Protocol Code 2020-30) and the University of the Philippines Manila Research Ethics Board (UPMREB Code 2020-0320-01-SJREB).

## REFERENCES

1. She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. *Clin. Transl. Med.* 2020;9(1). doi:10.1186/s40169-020-00271-z
2. Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. *BMJ*. Published online March 12, 2020:m1036. doi:10.1136/bmj.m1036
3. Connor J, Madhavan S, Mokashi M, et al. Health risks and outcomes that disproportionately affect women during the Covid-19 pandemic: A review. *Soc. Sci. Med.* 2020;266:113364. doi:10.1016/j.socscimed.2020.113364
4. Fortier N. COVID-19, gender inequality, and the responsibility of the state. *Int. J. Wellbeing.* 2020;10(3):77-93. doi:10.5502/ijw.v10i3.1305
5. Phoswa WN, Khaliq OP. Is pregnancy a risk factor of COVID-19? *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2020;252:605-609. doi:10.1016/j.ejogrb.2020.06.058
6. Llamas-Clark EF, Singson RB, Heralde FM, et al. Risk factors of COVID-19 vertical transmission among pregnant and non-pregnant Filipinos in Metro Manila: a multicentre cohort study protocol. *BMJ Open.* 2022;12(4):e053389. doi:10.1136/bmjopen-2021-053389
7. Petersen MR, Deddens JA. A comparison of two methods for estimating prevalence ratios. *BMC Med. Res. Methodol.* 2008;8(1). doi:10.1186/1471-2288-8-9
8. Albert, JRG, Vizmanos JFV. Do men and women in the Philippines have equal economic opportunities?. *Philippine Institute for Development Studies Policy Notes.*



- 1  
2  
3 2017;2017(9). [https://www.pids.gov.ph/publication/policy-notes/do-men-and-women-](https://www.pids.gov.ph/publication/policy-notes/do-men-and-women-in-the-philippines-have-equal-economic-opportunities)  
4 [in-the-philippines-have-equal-economic-opportunities](https://www.pids.gov.ph/publication/policy-notes/do-men-and-women-in-the-philippines-have-equal-economic-opportunities)  
5  
6  
7 9. World Economic Forum. *Global gender gap report 2022*.  
8 [https://www3.weforum.org/docs/WEF\\_GGGR\\_2022.pdf](https://www3.weforum.org/docs/WEF_GGGR_2022.pdf). Published 2022. Accessed  
9 July 14, 2022.  
10  
11  
12 10. Mielcarska K, Żelaźniewicz A, Pawłowski B. Risk taking propensity in pregnancy —  
13 Longitudinal study. *Pers. Individ. Differ.* 2017;110:7-11.  
14 doi:10.1016/j.paid.2017.01.012  
15  
16  
17 11. Lyerly AD, Mitchell LM, Armstrong EM, et al. Risk and the Pregnant Body. *Hastings*  
18 *Center Report*. 2009;39(6):34-42. doi:10.1353/hcr.0.0211  
19  
20  
21 12. Burns J, Movsisyan A, Stratil JM, et al. International travel-related control measures to  
22 contain the COVID-19 pandemic: a rapid review. *CDSR*. 2021;2021(3).  
23 doi:10.1002/14651858.cd013717.pub2  
24  
25  
26 13. Klinger C, Burns J, Movsisyan A, et al. Unintended health and societal consequences  
27 of international travel measures during the COVID-19 pandemic: a scoping review. *J.*  
28 *of Travel Med.* 2021;28(7). doi:10.1093/jtm/taab123  
29  
30  
31 14. The gendered impact of coronavirus disease (COVID-19): do estrogens play a role?  
32 The *Eur. J. Contracept. Reprod. Health Care*. Published 2020. Accessed October 24,  
33 2022. <https://www.tandfonline.com/doi/full/10.1080/13625187.2020.1766017>  
34  
35  
36 15. Kaushic C, Roth KL, Anipindi V, Xiu F. Increased prevalence of sexually transmitted  
37 viral infections in women: the role of female sex hormones in regulating susceptibility  
38 and immune responses. *J. Reprod. Immunol.* 2011;88(2):204-209.  
39 doi:10.1016/j.jri.2010.12.004  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

			Page
		Reporting Item	Number
<b>Title and abstract</b>			
Title	<a href="#">#1a</a>	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and balanced summary	2

of what was done and what was found

## Introduction

Background / [#2](#) Explain the scientific background and rationale for the 3  
 rationale investigation being reported

Objectives [#3](#) State specific objectives, including any prespecified 3  
 hypotheses

## Methods

Study design [#4](#) Present key elements of study design early in the paper 4

Setting [#5](#) Describe the setting, locations, and relevant dates, including 4  
 periods of recruitment, exposure, follow-up, and data collection

Eligibility criteria [#6a](#) Give the eligibility criteria, and the sources and methods of 4  
 selection of participants. Describe methods of follow-up.

Eligibility criteria [#6b](#) For matched studies, give matching criteria and number of 4  
 exposed and unexposed

Variables [#7](#) Clearly define all outcomes, exposures, predictors, potential 4  
 confounders, and effect modifiers. Give diagnostic criteria, if  
 applicable

Data sources / [#8](#) For each variable of interest give sources of data and details of 4  
 measurement methods of assessment (measurement). Describe  
 comparability of assessment methods if there is more than one  
 group. Give information separately for for exposed and  
 unexposed groups if applicable.

1	Bias	<a href="#">#9</a>	Describe any efforts to address potential sources of bias	4
2				
3				
4	Study size	<a href="#">#10</a>	Explain how the study size was arrived at	4
5				
6				
7	Quantitative	<a href="#">#11</a>	Explain how quantitative variables were handled in the	4
8	variables		analyses. If applicable, describe which groupings were chosen,	
9			and why	
10				
11				
12				
13				
14				
15	Statistical	<a href="#">#12a</a>	Describe all statistical methods, including those used to control	
16	methods		for confounding	
17				
18				
19				
20	4			
21				
22				
23	Statistical	<a href="#">#12b</a>	Describe any methods used to examine subgroups and	4
24	methods		interactions	
25				
26				
27				
28				
29	Statistical	<a href="#">#12c</a>	Explain how missing data were addressed	4
30	methods			
31				
32				
33				
34	Statistical	<a href="#">#12d</a>	If applicable, explain how loss to follow-up was addressed	4
35	methods			
36				
37				
38				
39	Statistical	<a href="#">#12e</a>	Describe any sensitivity analyses	
40	methods			
41				
42				
43				
44				
45	4			
46				
47				
48	<b>Results</b>			
49				
50				
51	Participants	<a href="#">#13a</a>	Report numbers of individuals at each stage of study—eg	5
52			numbers potentially eligible, examined for eligibility, confirmed	
53			eligible, included in the study, completing follow-up, and	
54			analysed. Give information separately for for exposed and	
55				
56				
57				
58				
59				
60				

unexposed groups if applicable.

1			
2			
3			
4	Participants	<a href="#">#13b</a>	Give reasons for non-participation at each stage 5
5			
6	Participants	<a href="#">#13c</a>	Consider use of a flow diagram
7			
8			
9			
10	5		
11			
12			
13	Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg demographic, 7
14			
15			clinical, social) and information on exposures and potential
16			confounders. Give information separately for exposed and
17			unexposed groups if applicable.
18			
19			
20			
21			
22			
23	Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing data for each
24			variable of interest
25			
26			
27			
28	5		
29			
30			
31	Descriptive data	<a href="#">#14c</a>	Summarise follow-up time (eg, average and total amount)
32			
33			
34	5		
35			
36			
37	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures
38			over time. Give information separately for exposed and
39			unexposed groups if applicable.
40			
41			
42			
43			
44			
45	6		
46			
47			
48	Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable, confounder- 7
49			
50			adjusted estimates and their precision (eg, 95% confidence
51			interval). Make clear which confounders were adjusted for and
52			why they were included
53			
54			
55			
56			
57			
58	Main results	<a href="#">#16b</a>	Report category boundaries when continuous variables were 7
59			
60			

1		categorized	
2			
3			
4	Main results	<a href="#">#16c</a> If relevant, consider translating estimates of relative risk into	
5		absolute risk for a meaningful time period	
6			
7			
8			
9	7		
10			
11			
12	Other analyses	<a href="#">#17</a> Report other analyses done—eg analyses of subgroups and	7
13		interactions, and sensitivity analyses	
14			
15			
16			
17	<b>Discussion</b>		
18			
19			
20	Key results	<a href="#">#18</a> Summarise key results with reference to study objectives	8
21			
22			
23	Limitations	<a href="#">#19</a> Discuss limitations of the study, taking into account sources of	8
24		potential bias or imprecision. Discuss both direction and	
25		magnitude of any potential bias.	
26			
27			
28			
29			
30			
31	Interpretation	<a href="#">#20</a> Give a cautious overall interpretation considering objectives,	8-10
32		limitations, multiplicity of analyses, results from similar studies,	
33		and other relevant evidence.	
34			
35			
36			
37			
38			
39	Generalisability	<a href="#">#21</a> Discuss the generalisability (external validity) of the study	8-10
40		results	
41			
42			
43			
44	<b>Other Information</b>		
45			
46			
47	Funding	<a href="#">#22</a> Give the source of funding and the role of the funders for the	10
48		present study and, if applicable, for the original study on which	
49		the present article is based	
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

1 The STROBE checklist is distributed under the terms of the Creative Commons Attribution License  
2  
3 CC-BY. This checklist was completed on 27. November 2022 using <https://www.goodreports.org/>, a  
4  
5 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# BMJ Open

## Factors Associated with Having COVID-19 Among Unvaccinated Pregnant and Non-Pregnant Women in Metro Manila, Philippines: A Multi-Center Longitudinal Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-070688.R1
Article Type:	Original research
Date Submitted by the Author:	08-Mar-2023
Complete List of Authors:	<p>Llamas-Clark, Erlidia; University of the Philippines Manila, Heralde, Francisco M.; University of the Philippines Manila College of Medicine, Department of Molecular Biology and Biochemistry Lumandas, Mayan U.; Research Institute for Tropical Medicine, Department of Virology</p> <p>Cagayan, Maria Stephanie Fay; University of the Philippines Manila College of Medicine, Department of Pharmacology and Toxicology Villanueva-Uy, Maria Esterlita T.; University of the Philippines Manila, Institute of Child Health and Human Development, National Institutes of Health</p> <p>Chavez-Coloma, Leilani; Jose R Reyes Memorial Medical Center Valencia, Eleyne; Jose R Reyes Memorial Medical Center Cabana, Charizze Anne; Jose R Reyes Memorial Medical Center Espinosa, Lea Bernadette; Jose R Reyes Memorial Medical Center Anzures, Cynthia; Dr Jose Fabella Memorial Hospital, Department of Obstetrics and Gynecology</p> <p>Andal, Maria Lu; Dr Jose Fabella Memorial Hospital</p> <p>Martin, Carolina Paula; Ospital ng Maynila Medical Center</p> <p>Suarez, Patricia Nevira; Ospital ng Maynila Medical Center</p> <p>Quanico, Celine; Ospital ng Maynila Medical Center</p> <p>Beltran, Julia; Ospital ng Maynila Medical Center</p> <p>de Guzman, Vanessa; Justice Jose Abad Santos General Hospital</p> <p>Capitulo, Ryan; Justice Jose Abad Santos General Hospital</p> <p>Dominguez, Arlene; Sta. Ana Hospital</p> <p>Recio, Abygail; Sta. Ana Hospital</p> <p>Feliciano, Jeremiah; University of the Philippines Manila College of Medicine</p> <p>Baja, Emmanuel; University of the Philippines Manila, Exposure Assessment, Epidemiology, and Risk Lab Institute of Clinical Epidemiology; University of the Philippines Manila, Department of Clinical Epidemiology</p> <p>Rosell-Ubial, Paulyn Jean; University of the Philippines Manila College of Public Health</p>
<b>Primary Subject Heading</b>:	Obstetrics and gynaecology
Secondary Subject Heading:	Public health, Infectious diseases, Epidemiology



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Keywords:	COVID-19, EPIDEMIOLOGIC STUDIES, Public health < INFECTIOUS DISEASES, OBSTETRICS

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# Factors Associated with Having COVID-19 Among Unvaccinated Pregnant and Non-Pregnant Women in Metro Manila, Philippines: A Multi-Center Longitudinal Cohort Study

Erlidia F. Llamas-Clark, MD, PhD<sup>1,5</sup>, Francisco M. Heralde III, MSc, PhD<sup>2</sup>, Mayan U. Lumandas, MD, MSc<sup>3</sup>, Maria Stephanie Fay S. Cagayan, MD, PhD<sup>4</sup>, Maria Esterlita T. Villanueva-Uy, MD, MPH<sup>5</sup>, Leilani C. Chavez-Coloma, MD<sup>6</sup>, Eleyne I. Valencia, MD<sup>6</sup>, Charizze Anne S. Cabana, MD<sup>6</sup>, Lea Bernadette H. Espinosa, MD<sup>6</sup>, Cynthia U. Anzures, MD<sup>7</sup>, Maria Lu D. Andal, MD<sup>7</sup>, Carolina Paula C. Martin, MD<sup>8</sup>, Patricia Nevira V. Suarez, MD<sup>8</sup>, Celine D. Quanico, MD<sup>8</sup>, Julia B. Beltran, MD<sup>8</sup>, Vanessa D. de Guzman, MD<sup>9</sup>, Ryan B. Capitulo, MD<sup>9</sup>, Arlene R. Dominguez, MD<sup>10</sup>, Abygail L. Recio, MD<sup>10</sup>, Jeremiah F. Feliciano, BSc<sup>11</sup>, Emmanuel S. Baja, MSc, ScD<sup>12,13</sup>, Pauly Jean B. Rosell-Ubial, MD, MPH<sup>14</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, College of Medicine, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>2</sup>Department of Molecular Biology and Biochemistry, College of Medicine, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>3</sup>Department of Virology, Research Institute for Tropical Medicine, Muntinlupa City, 1781 Philippines

<sup>4</sup>Department of Pharmacology and Toxicology, College of Medicine, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>5</sup>Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>6</sup>Jose R. Reyes Memorial Medical Center, Rizal Ave, Santa Cruz, City of Manila, 1000 Philippines

<sup>7</sup>Dr. Jose Fabella Memorial Hospital, Lope de Vega St, Santa Cruz, City of Manila, 1003 Philippines

<sup>8</sup>Ospital ng Maynila Medical Center, 719 Quirino Avenue, corner Roxas Blvd, Malate, City of Manila, 1004 Philippines

<sup>9</sup>Justice Jose Abad Santos General Hospital, Numancia St, Binondo, City of Manila, 1008 Philippines

<sup>10</sup>Sta. Ana Hospital, New Panaderos Ext, Santa Ana, City of Manila, 1009 Philippines

<sup>11</sup>College of Medicine, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>12</sup>Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>13</sup>Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, City of Manila, 1000 Philippines

<sup>14</sup>College of Public Health, University of the Philippines Manila, City of Manila, 1000 Philippines

Corresponding and Primary author:

Erlidia F. Llamas-Clark, MD, PhD | eflamasclark@up.edu.ph; +63 9399148195

**WORD COUNT:** 2,357 words

**ABSTRACT:** 244 words

**TABLE AND FIGURE:** 1 Table, 1 Supplementary Table

**REFERENCES:** 27

## ABSTRACT

**Objective.** To determine potential risk factors associated with having COVID-19 among unvaccinated pregnant and non-pregnant women.

**Design.** A multicenter prospective cohort study among eligible women in Metro Manila, Philippines, from 2020 to 2022.

**Setting.** Five national and local hospital research sites altogether recruited and screened 500 consenting eligible individuals.

**Participants.** Pregnant and non-pregnant participants meeting the eligibility criteria were admitted for an RT-PCR determination of SARS-CoV-2, pregnancy testing and ultrasound, and an interview with an administered questionnaire.

**Exposures.** Primary exposure was pregnancy; secondary exposures involve sociodemographic, lifestyle, and obstetric-gynecologic factors.

**Outcome measure.** Outcome being measured was COVID-19 status.

**Results.** The significant COVID-19 risk factors were: pregnancy (PR=1.184, 95CI[1.096,1.279]), having a white-collar job (PR=1.123, 95CI[1.02,1.235]), traveling abroad (PR=1.369, 95CI[1.083, 1.173]), and being infected by at least one vaccine-preventable disease (VPD) (PR=1.208, 95CI[1.113,1.310]). Protective factors included having graduate-level education (PR=0.787, 95CI[0.649,0.954]), immunization against a VPD (PR=0.795, 95CI[0.733,0.862]), and practicing contraception (PR=0.889, 95CI[0.824,0.960]).

**Conclusion.** This study is the first in the country to determine the risks influencing COVID-19 infection among unvaccinated pregnant and non-pregnant women. Pregnancy is a significant risk for COVID-19 among women in Metro Manila. Educational attainment and positive health behaviors seem to confer protection. Occupations and activities that increase the frequency of interactions, as well as prior history of communicable diseases may predispose women to COVID-19. Further studies are needed to elucidate the development of the disease in pregnant women, including the maternal and neonatal effects of COVID-19 via potential vertical mechanisms of transmission.

**KEYWORDS** COVID-19, Pregnancy, Prospective studies, Risk factors

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- This article provides the first Philippine multi-center study in public hospitals in the National Capital Region to serve as a baseline for the determination of risk factors of

COVID-19 in women that incorporates in the analysis the pre-existing conditions and pressures experienced by Filipino women as a driving force behind COVID-19 risk.

- The study was conducted during the unpredictable height of the pandemic which may have introduced variability in the collection of exposed respondents, owing to the duration of the study which spanned six surges with three different prevailing variants, and pre-existing burdens of healthcare which may have caused consistently few enrollments.
- Further studies with an emphasis on the longitudinal nature of the disease throughout the gestation period to determine the differential progression of the disease in terms of gestational development may supplement the methodological approaches of the study.

## INTRODUCTION

**Background.** The rapid transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused cases of Coronavirus Disease 2019 (COVID-19) to rise in many countries since it was first reported in Wuhan, China, in December 2019<sup>1</sup>. By the time the WHO declared it a pandemic, significant repercussions were already observed in worldwide social and economic life<sup>2</sup>. The multifaceted nature of this pandemic gives rise to concerns about identifying relevant risk factors, especially for the vulnerable and underrepresented groups. Men have higher mortality risks when infected, but women may have higher risks of worse health outcomes and less healthcare access due to pre-existing socioeconomic gaps exacerbated by the pandemic<sup>3,4</sup>. At par or greater risks are pregnant women and their unborn; both susceptible to infection due to their weakened immune system<sup>5</sup>. However, these findings are largely dominated by white/Caucasian populations resulting in the underrepresentation of other races and ethnic minorities<sup>6</sup>. Evidence of sex- and pregnancy-based differences in COVID-19 vulnerability indicate a need to determine the relevant socio-demographic, lifestyle, and obstetric-gynecologic risk factors, especially in the Philippine context.

Two years have passed since the pandemic started, with several variants emerging such as the Alpha, Beta, Delta, and Omicron, that resulted in several surges that took the lives of millions<sup>7</sup>. In the Philippines, the Delta variant dominated COVID-19 cases in 2021 while the Omicron variant dominated in 2022<sup>8,9</sup>. Despite the numerous variants circulating in the country, genomic sequencing of COVID-19 variants remains limited and not part of routine case reporting of the Department of Health<sup>10</sup>. Regardless of this limitation, there are limited studies that identified the common risks attributed to COVID-19 infection in the local

1  
2  
3 population, especially with unvaccinated pregnant women and their unborn. Furthermore,  
4 studies on the matter are yet to incorporate the intersectionality of pre-existing socioeconomic  
5 pressures on women which may compound the risk determination for the disease.  
6  
7

8 **Objective.** This study aimed to identify the risk factors associated with COVID-19 in  
9 unvaccinated pregnant and non-pregnant women in five hospitals in the City of Manila,  
10 Philippines. More specifically, this explored the sociodemographic and lifestyle factors that  
11 potentially predisposed women to COVID-19 infection.  
12  
13  
14

## 15 16 17 **METHODS**

18 **Study design and setting.** This study is part of a comprehensive prospective  
19 multicenter cohort study protocol to determine the risk factors, clinical manifestations,  
20 progression, and maternal-neonatal outcomes of COVID-19 vertical transmission among  
21 pregnant and non-pregnant women in Metro Manila<sup>11</sup>. Specific details on the procedures can  
22 be found in the said protocol.  
23  
24  
25  
26

27 **Target population and eligibility criteria.** Women at least 18 years old regardless of  
28 pregnancy status who consulted among the five public hospital research sites under the  
29 Department of Health (DOH) or the Manila City Government, ranging from November 30,  
30 2020, to March 31, 2022. Included are women who will consult for any medical or Ob-Gyn  
31 condition at the Departments of Internal Medicine, Ob-Gyn emergency room, labor, or delivery  
32 rooms without any uterine or adnexal lesions which would influence the course of the disease.  
33 Excluded are those who are less than 18 years old, who cannot or are not able to provide  
34 informed consent, who cannot commit to the length of time of the study, who will not deliver  
35 in any of the five hospital sites, or those with malignant or congenital reproductive tract  
36 abnormalities or infection as seen on ultrasound. Incidental findings were referred to  
37 appropriate subspecialty services. All study participants meeting the inclusion criteria were  
38 admitted to the study following a thorough briefing and with their written and continuing  
39 consent. Respondents were informed of their right to withdraw at any time without fear of  
40 compromising medical care and are encouraged to state their reasons for documentation.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 **Sample size calculation, handling of bias, and nonresponse.** A two-sided 95% CI  
52 with an 80% power and a ratio of 1, and a least extreme OR to be detected at around 2.0, the  
53 computed sample size was 576. To accommodate a 10% nonresponse rate, the final sample  
54 size was 640, of which 320 were to be pregnant, and which were proportionately allocated to  
55 the hospital sites. The hospital sites were selected because they have the highest capacities of  
56 public healthcare institutions and were anticipated to admit individuals representing the target  
57  
58  
59  
60

1  
2  
3 population. Pregnant women were all invited regardless of age of gestation, provided they met  
4 the inclusion criteria, to comprehensively capture information about COVID-19 at all  
5 developmental stages of pregnancy. The duration of the study has exposed the population to at  
6 least three prevailing COVID-19 variants and their corresponding surges. However, as the  
7 Department of Health has not made genomic surveillance routine operation on identification  
8 of cases, and that during the height of the pandemic, such operations were beyond the capacity  
9 of the study, further stratification of respondents according to SARS-CoV-2 strain were not  
10 carried out. The researchers were cognizant of the differing virulence and progressions of these  
11 strains. However, more pressing was the need to determine the common denominator of  
12 predisposing risks and protective factors to the local population.

21 **Sampling and data collection.** The Research Institute of Tropical Medicine (RITM)  
22 processed the collected samples using reverse-transcription PCR for diagnosis and analyses of  
23 unconventional samples. Laboratory determination of SARS-CoV-2 and pregnancy status were  
24 carried out after collection of samples from the participants. They were also given a validated  
25 self-administered structured COVID-19 infection in adults questionnaire adapted from the New  
26 South Wales Department of Health<sup>11</sup>. The questionnaire will profile the socio-demographic,  
27 lifestyle, obstetric-gynecologic, medical history, and pregnancy-related characteristics of each  
28 participant.

34 **Patient and public involvement.** Patients and(or) the public were not involved in the  
35 design.

37 **Outcome and exposures.** Outcome measurement was COVID-19 status, which is  
38 confirmed from the RT-PCR test. Primary exposure was pregnancy status, determined from  
39 pregnancy test and(or) ultrasound. Secondary exposures were socio-demographic, lifestyle,  
40 and obstetric-gynecologic factors, as will be discussed in later sections.

44 **Statistical analysis.** The data is expressed as the summation of all respondents that  
45 exhibited either infected or uninfected outcomes throughout the entire study duration as the  
46 prevalence period. Quantitative variables (i.e. age, income) were categorized following the  
47 protocol for this study<sup>11</sup>. Descriptive statistics profiled the socio-demographic, lifestyle, and  
48 obstetric-gynecologic characteristics of pregnant and non-pregnant cohorts. The crude  
49 prevalence ratio (cPR) and the corresponding 95% confidence interval (95CI) were calculated  
50 after regressing a bivariable generalized linear model using a Poisson distribution with robust  
51 variance correction and a log link function between the characteristics as predictors, and  
52 COVID-19 status as the outcome. This model was the best option to minimize the  
53 overestimation of the true prevalence ratio among other alternatives<sup>12</sup>. The same regression  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 model was used to create adjusted prevalence ratios (aPRs) and to determine which among the  
4 characteristics are better risk indicators of COVID-19 susceptibility among the women in the  
5 study.  
6  
7  
8  
9

## 10 RESULTS

11 Five hundred respondents were included from the five hospitals throughout the study period.  
12 Of them, 267 (53.5%) were pregnant. Among pregnant women, the median age of gestation  
13 was 39 weeks [QD=1 week], with the most recent being 16 weeks and the oldest being 40  
14 weeks and 5 days. After omitting missing observations in the variables of interest, only 352  
15 (70.4%) cases remained for regression analyses and calculation of prevalence ratios. Most  
16 participants were lost to follow-up, particularly during delivery, when most of them preferred  
17 to deliver out of the hospital research sites. **Supplemental Table 1** shows the socio-  
18 demographic and lifestyle characteristics of the respondents. Most respondents tested negative  
19 for COVID-19 during the study, which is also consistent for pregnant (29.4%) and nonpregnant  
20 (24.0%) cohorts. More than half of all respondents reside in Manila City (n=269, 54.3%) and  
21 were admitted to DOH partner hospitals, which are among the highest-capacity tertiary  
22 institutions in the country. Furthermore, most respondents live in households, are Catholic,  
23 have never smoked nor drank alcoholic beverages, have not consumed illicit drugs, have an O  
24 blood type or have never left the country during the pandemic. Among pregnant respondents,  
25 the majority were younger, high school graduates, unemployed, single, making less than  
26 USD90.91 (PHP5,000) per month, not practicing contraception, have been infected or  
27 immunized against at least one vaccine-preventable disease (VPD), have been twice pregnant  
28 at most, or with up to two viable pregnancies.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 **Table 1** shows crude and adjusted prevalence ratios for potential risk factors of  
44 COVID-19. Significant risk factors among unvaccinated women include being pregnant,  
45 white-collar worker, having been infected with at least one VPD, and leaving the country  
46 during the pandemic. Protective factors are having graduate-level education, practicing  
47 contraception, and being immunized for at least one VPD. Blood type does not seem to be a  
48 significant predictor of COVID-19 among women, as well as gravidity, parity, smoking  
49 history, and alcohol use.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 1.** Crude (cPR) and adjusted (aPR) prevalence ratios with 95% confidence intervals for associations between COVID-19 and covariates.

Characteristics	Total, n=352	COVID-19- negative, n=220	COVID-19- positive, n=132	cPR[95CI]	aPR[95CI]
<b>OBSTETRIC-GYNECOLOGIC FACTORS</b>					
<i>Pregnancy status</i>					
Non-pregnant	120 (34.1)	85 (24.1)	35 (9.9)	1.000	1.000
Pregnant	232 (65.9)	135 (38.4)	97 (27.6)	1.149 [1.063, 1.242]*	1.184[1.096, 1.279]*
<i>Gravidity</i>					
Two at most	225 (63.9)	142 (40.3)	83 (23.6)	1.000	1.000
At least 3	127 (36.1)	78 (22.2)	49 (13.9)	1.012 [0.938, 1.093]	1.075 [0.975, 1.185]
<i>Parity</i>					
Two at most	270 (76.7)	165 (46.9)	105 (29.8)	1.000	1.000
At least 3	82 (23.3)	55 (15.6)	27 (7.7)	0.957 [0.877, 1.044]	0.934 [0.842, 1.036]
<b>SOCIODEMOGRAPHIC FACTORS</b>					
<i>Age</i>					
18-30	189 (53.7)	118 (33.5)	71 (20.2)	1.000	1.000
31-48	140 (39.8)	87 (24.7)	53 (15.1)	1.002 [0.928, 1.082]	0.968 [0.896, 1.045]
>49	23 (6.5)	15 (4.3)	8 (2.3)	0.980 [0.841, 1.142]	0.999 [0.857, 1.163]
<i>Resides in Manila</i>					
No	175 (51.0)	128 (36.4)	48 (13.6)	1.000	1.000
Yes	168 (48.9)	92 (26.1)	84 (23.9)	1.161 [1.080, 1.247]*	1.055 [0.990, 1.123]
<i>Educational attainment</i>					
Elementary	16 (4.5)	9 (2.6)	7 (1.9)	1.000	1.000
High school	171 (48.6)	110 (31.3)	61 (17.3)	0.944 [0.791, 1.127]	0.917 [0.807, 1.043]
College	143 (40.6)	83 (23.6)	60 (17.0)	0.988 [0.826, 1.180]	0.927 [0.809, 1.063]
Post-graduate	19 (5.4)	16 (4.5)	3 (0.9)	0.805 [0.646, 1.004]	0.787 [0.649, 0.954]*
Vocational**	3 (0.9)	2 (0.6)	1 (0.3)	0.928 [0.601, 1.432]	0.798 [0.62, 1.027]
<i>Type of occupation***</i>					
Unemployed/Unstable	243 (69.0)	160 (45.5)	83 (23.6)	1.000	1.000
Blue-collar job	25 (7.1)	14 (3.9)	11 (3.1)	1.073 [0.931, 1.237]	1.02 [0.889, 1.169]
White-collar job	84 (23.9)	46 (13.1)	38 (10.8)	1.083 [0.994, 1.179]	1.123 [1.02, 1.235]*
<i>Marital status</i>					
Single	207 (58.8)	133 (37.8)	74 (21.0)	1.000	1.000
Married	126 (35.8)	73 (20.7)	53 (15.1)	1.047 [0.969, 1.131]	1.057 [0.979, 1.142]
Cohabiting	15 (4.3)	12 (3.4)	12 (0.9)	0.884 [0.742, 1.053]	0.906 [0.759, 1.082]
Widowed	4 (1.1)	2 (0.6)	2 (0.6)	1.105 [0.794, 1.537]	0.990 [0.610, 1.606]
<i>Religion</i>					
Catholic	324 (92.0)	202 (57.4)	122 (34.7)	1.000	1.000
Protestant	5 (1.4)	2 (0.6)	3 (0.9)	1.162 [0.886, 1.524]	1.193 [0.913, 1.558]
Muslim	9 (2.6)	6 (1.7)	3 (0.9)	0.969 [0.766, 1.224]	1.056 [0.896, 1.244]
Others	14 (3.9)	10 (2.8)	4 (1.1)	0.934 [0.774, 1.127]	0.982 [0.841, 1.147]
<i>Socioeconomic status</i>					
Less than 90.91 USD (5,000 PHP)	198 (56.3)	136 (38.6)	62 (17.6)	1.000	1.000
90.91 USD to 363.62 USD (5,000 to 20,000 PHP)	101 (28.7)	54 (15.3)	47 (13.4)	1.116 [1.027, 1.212]*	1.060 [0.985, 1.141]
Above 363.62 USD (20,000 PHP)	53 (15.1)	30 (8.5)	23 (6.5)	1.092 [0.983, 1.213]	1.048 [0.935, 1.174]
<b>LIFESTYLE FACTORS</b>					

<b>Using contraception</b>					
No	282 (80.1)	166 (47.2)	116 (32.9)	1.000	1.000
Yes	70 (19.9)	54 (15.3)	16 (4.5)	0.870 [0.796, 0.952]*	0.889 [0.824, 0.960]*
<b>Smoking history</b>					
Never smoker	337 (95.7)	209 (59.4)	128 (36.4)	1.000	1.000
Ever smoker	15 (4.3)	11 (3.1)	4 (1.1)	0.918 [0.766, 1.100]	1.124 [0.955, 1.324]
<b>Alcohol use</b>					
Never alcoholic	301 (85.5)	185 (52.6)	116 (32.9)	1.000	1.000
Ever alcoholic	51 (14.5)	35 (9.9)	16 (4.5)	0.948 [0.854, 1.053]	1.002 [0.909, 1.104]
<b>Immunized VPD &gt; 1</b>					
No	219 (62.2)	103 (29.3)	116 (32.9)	1.000	1.000
Yes	133 (37.8)	117 (33.2)	16 (4.4)	0.732 [0.686, 0.782]*	0.795 [0.733, 0.862]*
<b>History VPD &gt; 1</b>					
No	238 (67.6)	181 (51.4)	57 (16.2)	1.000	1.000
Yes	114 (32.4)	39 (11.1)	75 (21.3)	1.338 [1.249, 1.432]*	1.208 [1.113, 1.310]*
<b>Blood type</b>					
A	82 (23.3)	58 (16.5)	24 (6.8)	1.000	1.000
B	68 (19.3)	42 (11.9)	26 (7.4)	1.069 [0.955, 1.197]	1.047 [0.958, 1.146]
O	181 (51.4)	106 (30.1)	75 (21.3)	1.094 [0.998, 1.199]	1.028 [0.958, 1.103]
AB	21 (5.9)	14 (3.9)	7 (1.9)	1.031 [0.871, 1.222]	0.967 [0.837, 1.117]
<b>Travel history</b>					
No	349 (99.1)	220 (62.5)	129 (36.6)	1.000	1.000
Yes	3 (0.9)	0 (0.0)	3 (0.9)	1.460 [1.407, 1.515]*	1.369 [1.083, 1.173]*

\*Significant at 5% level of significance.

\*\*Vocational education refers to the short-course for semi-skilled or skilled technical-vocational programs and certifications offered by the Technical Education and Skills Development Authority (TESDA).

\*\*\*As per the International Labor Organization, Blue-collar workers are those whose jobs are mostly unskilled, semi-skilled or skilled manual work in various trades, equipment operation, and maintenance. White-collar workers are those whose jobs involve non-manual office, clerical, sales, semi-technical, professional, or supervisory activities<sup>13</sup>.

## DISCUSSION

This is the first multicenter study in the country to address relevant gaps in the literature by elucidating the systemic inequities and circumstances that contextualize the differential risks in sociodemographic, lifestyle, and obstetric-gynecologic factors between pregnant and non-pregnant women during the early pandemic when vaccines were still unavailable. Further research with consideration of the temporal interaction of the disease with pregnancy is suggested in view of the cumulative nature of this cohort study. This study found that risk factors for unvaccinated women include pregnancy, white-collar jobs, overseas travel, and VPD history. Protective factors, on the other hand, include graduate school education, immunization against VPD, and contraception practice.

Population profile in this present study reveal that pregnant women were younger, single, unemployed or hold unstable jobs, or make lesser monthly income. Before the pandemic, there were already fewer women in the Philippine labor force in 2015<sup>14</sup>. Filipinas

1  
2  
3 also had a higher incidence of vulnerable employment like self-employment and unpaid home  
4 duties, often associated with insufficient income and unsafe working conditions. Prevailing  
5 conservative gender roles also translate to women usually being homemakers, even as the  
6 Philippines ranks first in gender equality among Asian countries in 2022<sup>4,15</sup>. This cultural  
7 practice relegates women from the job market, causing insecure, lower-income employment  
8 with lesser bargaining power in most national economies<sup>4</sup>. Pregnancy compounds these  
9 intersecting inequities due to behavioral tendencies to take lesser risks even in decisions that  
10 may benefit their physical or financial wellbeing<sup>16,17</sup>.

11  
12  
13  
14  
15  
16  
17 Multivariable analysis and risk determination found that COVID-19-positive women  
18 may more likely present as pregnant, white-collar workers, have had at least one VPD  
19 infection, or have traveled outside the country during the pandemic. Pregnancy, as a risk factor,  
20 supports other studies' findings which have variously been attributed to a more vulnerable  
21 immune constitution during gestation<sup>5</sup>. COVID-19-positive women had higher rates of ICU  
22 admission, intubation, ICU hospitalization, and preterm birth than their non-pregnant  
23 counterparts, according to cohort studies conducted in the United States<sup>18</sup>. Moreover, pregnant  
24 women with COVID-19 are more likely to be hospitalized and given moderate ventilation<sup>19</sup>.  
25 On the other hand, white-collar workers being at higher risk may be explained by the general  
26 nature of their occupations in healthcare, essential bureaucracy as part of a skeleton workforce,  
27 and similar jobs that result in increased interaction with suspect cases of the disease. Healthcare  
28 workers are at high risk of contracting COVID-19 due to contact with patients with the disease,  
29 with nurses and nonemergency wards personnel being the most commonly infected albeit  
30 mostly asymptomatic<sup>20</sup>. For this reason, it is also rational, as other studies found to varying  
31 significance, to expect international travel as a risk factor for COVID-19 infection and its  
32 consequent spread<sup>21,22</sup>. Returning travelers and pilgrims have been found to trigger COVID-19  
33 outbreaks in various countries<sup>23</sup>. Having a history of VPD infection as a risk is a novel finding  
34 that warrants further research. The researchers hypothesize that the social and environmental  
35 influences that led to a prior VPD infection may have been the same conditions that caused  
36 COVID-19 transmission, especially among the densely populated shanty towns of Manila City  
37 with poor sanitation systems and ventilation.

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53 In the same vein, immunization for at least one VPD appears to be protective against  
54 COVID-19, which likewise requires further immunologic and socio-behavioral investigations.  
55 Furthermore, graduate-level education also lowers infection risk, suggesting a positive effect  
56 of higher education in forming informed decisions among individuals. Higher educated people  
57 are more likely to follow protective measures against COVID-19 such as using disinfectants  
58  
59  
60

1  
2  
3 and wearing masks in contrast to lower educated people, who are less likely to adapt social  
4 distancing, increase hand washing and disinfection, and avoid gatherings, meetings, and  
5 personal contact<sup>24</sup>. Subsequently, contraception also lowers the risk of COVID-19 presumably  
6 due to the positive health outcomes inherent in the behavior that could have translated into  
7 COVID-19-safe practices. People who practice safe sex through contraceptives consider  
8 COVID-19 exposure as part of the risky sexual behavior which they are conditioned to refrain  
9 from<sup>25</sup>. Furthermore, some studies suggest that higher or physiologic estrogen levels, especially  
10 during consumption of combined hormonal contraceptives (CHCs) confer a humoral immune-  
11 reactive response by inducing higher antibody levels<sup>26,27</sup>.

12  
13  
14  
15  
16  
17  
18  
19 While this study provides information about the risk and protective factors in women  
20 in the Philippines, the limitations of this study pose restrictions to the external validity of the  
21 results. First, since data collection was performed during the early pandemic, the population  
22 are yet to be vaccinated. Second, genomic surveillance is not routinely done by the Department  
23 of Health and therefore unavailable for analysis. Because of this, this study only focuses on  
24 identifying predisposing factors of COVID-19 infection regardless of variants. Second, the  
25 longitudinal progression of the disease associated with the stage of pregnancy was not  
26 addressed since the study is time-limited. Lastly, there is no baseline characterization of the  
27 local population yet as of conducting this study. Because of this, the external validity of this  
28 study only includes unvaccinated women in the Philippines exposed to dominant variants at  
29 the time of data collection.  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 CONCLUSION

40  
41 Pregnancy is a significant risk factor for COVID-19 infection among women, as is  
42 being a white-collar worker, being infected by at least one VPD, and traveling outside the  
43 country during the pandemic. On the other hand, protective factors include graduate-level  
44 education, practicing contraception, and being immunized for at least one VPD.  
45  
46  
47

48 Our findings are useful in providing baseline findings on the characteristics that  
49 exacerbate and relieve the susceptibility of unvaccinated Filipinas to COVID-19. This will  
50 inform the development of public health response and vaccination efforts with consideration  
51 to vulnerable populations, including pregnant women. Further investigations as to the clinical  
52 manifestations, maternal and neonatal outcomes, and the possibility of vertical transmission of  
53 COVID-19 are recommended.  
54  
55  
56  
57  
58  
59  
60

## COMPETING INTERESTS

1  
2  
3 The authors declare no potential conflicts of interest regarding the research, authorship,  
4 and publication of this article.  
5  
6  
7

## 8 **AUTHOR CONTRIBUTIONS**

9  
10 EFL-C is the principal investigator and first author of this study who gave instrumental  
11 contributions to the concept, research design and methodology including the implementation  
12 and management of this study. FMH, ESB, METV-U, MSFSC, MUL and PJBR-U assisted in  
13 specific components of the study. LCC-C, EIV, CASC, LBHE, CUA, MLDA, CPCM, PNVS,  
14 CDQ, JBB, VDdG, RBC, ARD, and ALR implemented the research methodology and provided  
15 practical insights and discussion which were considered in the study. ESB, JFF and EFLC  
16 conducted statistical data analyses and interpretation. JFF and EFL-C drafted the article and  
17 visualization and provided contextual interpretations into the study findings. All have critically  
18 revised and approved the final version of the manuscript.  
19  
20  
21  
22  
23  
24  
25  
26

## 27 **FUNDING**

28  
29 This study was made possible by grants from the Australian Awards and Alumni  
30 Engagement Program (Award/Grant Number: N/A), Department of Science and Technology -  
31 Philippine Council for Health Research and Development (DOST-PCHRD) (Award/Grant  
32 Number: N/A), and the Philippine Obstetrical and Gynecological Society (POGS)  
33 (Award/Grant Number: N/A).  
34  
35  
36  
37  
38  
39

## 40 **ACKNOWLEDGEMENTS**

41 The authors would like to thank the following: Research Institute of Tropical  
42 Medicine—Dr Celia Carlos; Manila City Officials headed by former Mayor Francisco 'Isko  
43 Moreno' Domagoso; Office of the Mayor Honorable Honey Lacuna-Pangan, the Manila City  
44 Councilors headed by Councilor Joel Chua, and Manila City Health Department Staff—Dr  
45 Arnold Pangan, Dr Gina Pardilla, and Dr Rosalina R Tan and other public health staff. Our  
46 gratitude to the administrators, resident physicians, and medical officers in cooperating in the  
47 endeavor. Much appreciation to Ms Kyla Javier and the research staff, as well as the staff of  
48 the project site hospitals, and all participants who contributed in this multicenter COVID19  
49 and women study for the Philippines.  
50  
51  
52  
53  
54  
55  
56  
57

## 58 **PATIENT CONSENT FOR PUBLICATION**

59 Obtained.  
60

## DATA AVAILABILITY STATEMENT

Data are available upon reasonable request.

## ETHICS APPROVAL

The study was approved by the DOH Single Joint Research Ethics Board (DOH-SJREB Protocol Code 2020-30) and the University of the Philippines Manila Research Ethics Board (UPMREB Code 2020-0320-01-SJREB).

## REFERENCES

1. She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. *Clin. Transl. Med.* 2020;9(1). doi:10.1186/s40169-020-00271-z
2. Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. *BMJ*. Published online March 12, 2020:m1036. doi:10.1136/bmj.m1036
3. Connor J, Madhavan S, Mokashi M, et al. Health risks and outcomes that disproportionately affect women during the Covid-19 pandemic: A review. *Soc. Sci. Med.* 2020;266:113364. doi:10.1016/j.socscimed.2020.113364
4. Fortier N. COVID-19, gender inequality, and the responsibility of the state. *Int. J. Wellbeing.* 2020;10(3):77-93. doi:10.5502/ijw.v10i3.1305
5. Phoswa WN, Khaliq OP. Is pregnancy a risk factor of COVID-19? *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2020;252:605-609. doi:10.1016/j.ejogrb.2020.06.058
6. Moore JT, Ricaldi JN, Rose CE, et al. Disparities in incidence of COVID-19 among underrepresented racial/ethnic groups in counties identified as hotspots during June 5–18, 2020 — 22 states, February–June 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(33):1122-1126. doi:10.15585/mmwr.mm6933e1
7. Wacharapluesadee S, Hirunpatrawong P, Petcharat S, et al. Simultaneous detection of omicron and other SARS-CoV-2 variants by multiplex PCR MassARRAY technology. *Sci Rep.* 2023;13(1):2089. doi:10.1038/s41598-023-28715-9
8. Li Y-T, Polotan FG, Sotelo GI, et al. Lineage BA.2 dominated the omicron sars-cov-2 epidemic wave in the Philippines. *Virus Evol.* 2022;8(2):veac078. doi:10.1093/ve/veac078

- 1  
2  
3 9. Morales NJ, Dela Cruz E. Philippines reports record virus cases as Delta variant  
4 spreads. *Reuters*. August 23, 2021.
- 5  
6 10. Tablizo FA, Lapid CM, Maralit BA, et al. Analysis of SARS-COV-2 genome  
7 sequences from the Philippines: Genetic surveillance and transmission dynamics.  
8 *medRxiv*. 2020. doi:10.1101/2020.08.22.20180034
- 9  
10 11. Llamas-Clark EF, Singson RB, Heralde FM, et al. Risk factors of COVID-19 vertical  
12 transmission among pregnant and non-pregnant Filipinos in Metro Manila: a  
13 multicentre cohort study protocol. *BMJ Open*. 2022;12(4):e053389.  
14 doi:10.1136/bmjopen-2021-053389
- 15  
16 12. Petersen MR, Deddens JA. A comparison of two methods for estimating prevalence  
17 ratios. *BMC Med. Res. Methodol*. 2008;8(1). doi:10.1186/1471-2288-8-9
- 18  
19 13. Heron R & Unger L Glossary of Labour Administration and Related Terms.  
20 International Labour Organization. 1999. [https://www.ilo.org/wcmsp5/groups/public/-](https://www.ilo.org/wcmsp5/groups/public/-ed_dialogue/---lab_admin/documents/publication/wcms_111331.pdf)  
21 [--ed\\_dialogue/---lab\\_admin/documents/publication/wcms\\_111331.pdf](https://www.ilo.org/wcmsp5/groups/public/-ed_dialogue/---lab_admin/documents/publication/wcms_111331.pdf)
- 22  
23 14. Albert, JRG, Vizmanos JFV. Do men and women in the Philippines have equal  
24 economic opportunities? *Philippine Institute for Development Studies Policy Notes*.  
25 2017;2017(9). [https://www.pids.gov.ph/publication/policy-notes/do-men-and-women-](https://www.pids.gov.ph/publication/policy-notes/do-men-and-women-in-the-philippines-have-equal-economic-opportunities)  
26 [in-the-philippines-have-equal-economic-opportunities](https://www.pids.gov.ph/publication/policy-notes/do-men-and-women-in-the-philippines-have-equal-economic-opportunities)
- 27  
28 15. World Economic Forum. *Global gender gap report 2022*.  
29 [https://www3.weforum.org/docs/WEF\\_GGGR\\_2022.pdf](https://www3.weforum.org/docs/WEF_GGGR_2022.pdf). Published 2022. Accessed  
30 July 14, 2022.
- 31  
32 16. Mielcarska K, Żelaźniewicz A, Pawłowski B. Risk taking propensity in pregnancy —  
33 Longitudinal study. *Pers. Individ. Differ*. 2017;110:7-11.  
34 doi:10.1016/j.paid.2017.01.012
- 35  
36 17. Lysterly AD, Mitchell LM, Armstrong EM, et al. Risk and the Pregnant Body. *Hastings*  
37 *Center Report*. 2009;39(6):34-42. doi:10.1353/hcr.0.0211
- 38  
39 18. Chinn J, Sedighim S, Kirby KA, Hohmann S, Hameed AB, Jolley J, et al.  
40 Characteristics and outcomes of women with covid-19 giving birth at US academic  
41 centers during the COVID-19 pandemic. *JAMA Netw Open*. 2021;4(8):e2120456.  
42 doi:10.1001/jamanetworkopen.2021.20456
- 43  
44 19. Qeadan F, Mensah NA, Tingey B, Stanford JB. The risk of clinical complications and  
45 death among pregnant women with covid-19 in the cerner covid-19 cohort: A  
46 retrospective analysis. *BMC Pregnancy and Childbirth*. 2021;21(1). doi:  
47 10.1186/s12884-021-03772-y

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
20. Gómez-Ochoa SA, Franco OH, Rojas LZ, et al. Covid-19 in health-care workers: A living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. *Am J Epidemiol.* 2020;190(1):161-175. doi:10.1093/aje/kwaa191
  21. Burns J, Movsisyan A, Stratil JM, et al. International travel-related control measures to contain the COVID-19 pandemic: a rapid review. *CDSR.* 2021;2021(3). doi:10.1002/14651858.cd013717.pub2
  22. Klinger C, Burns J, Movsisyan A, et al. Unintended health and societal consequences of international travel measures during the COVID-19 pandemic: a scoping review. *J. of Travel Med.* 2021;28(7). doi:10.1093/jtm/taab123
  23. Wilder-Smith A. COVID-19 in comparison with other emerging viral diseases: Risk of geographic spread via travel. *Trop Dis Travel Med Vaccines.* 2021;7(1). doi:10.1186/s40794-020-00129-9
  24. Lüdecke D, von dem Knesebeck O. Protective Behavior in Course of the COVID-19 Outbreak—Survey Results From Germany. *Front Public Heal.* 2020;8. <https://www.frontiersin.org/articles/10.3389/fpubh.2020.572561>
  25. Bowling J, Montanaro E, Gattuso J, Gioia D, Guerrero Ordonez S. “Everything feels risky now”: Perceived “risky” sexual behavior during COVID-19 pandemic. *J Health Psychol.* 2021;27(6):1498-1506. doi:10.1177/13591053211004684
  26. The gendered impact of coronavirus disease (COVID-19): do estrogens play a role? *The Eur. J. Contracept. Reprod. Health Care.* Published 2020. Accessed October 24, 2022. <https://www.tandfonline.com/doi/full/10.1080/13625187.2020.1766017>
  27. Kaushic C, Roth KL, Anipindi V, Xiu F. Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses. *J. Reprod. Immunol.* 2011;88(2):204-209. doi:10.1016/j.jri.2010.12.004



**Supplemental Table 1.** Characteristics of respondents included in the study, stratified by pregnancy status.

Characteristics	Total, n=500	Non- pregnant, n=233	Pregnant, n=267
<b>SOCIODEMOGRAPHIC FACTORS</b>			
<i>Admitting hospital</i>			
DJFMH	166 (33.2)	78 (15.6)	88 (17.6)
JRRMMC	168 (33.6)	78 (15.6)	90 (18.0)
OMMC	58 (11.6)	26 (5.2)	32 (6.4)
SAH	59 (11.8)	29 (5.8)	30 (6.0)
JJASGH	49 (9.8)	22 (4.4)	27 (5.4)
<i>Age</i>			
18-30	246 (49.2)	77 (15.4)	169 (33.8)
31-48	202 (40.4)	105 (21.0)	97 (19.4)
>49	52 (10.4)	51 (10.2)	1 (0.2)
<i>Resides in Manila</i>			
No	226 (45.7)	89 (17.9)	137 (27.7)
Yes	269 (54.3)	139 (28.1)	130 (26.3)
Missing	5	5	0
<i>Address type</i>			
Household	494 (98.9)	228 (45.7)	266 (53.3)
Aged care facility	1 (0.2)	1 (0.2)	0 (0.0)
Other residence type	4 (0.8)	3 (0.6)	1 (0.2)
Missing	1	1	0
<i>Educational attainment</i>			
Elementary	33 (6.6)	18 (3.6)	15 (3.0)
High school	234 (46.8)	100 (20.0)	134 (26.8)
College	195 (39.0)	85 (17.0)	110 (22.0)
Graduate school	35 (7.0)	30 (6.0)	5 (1.0)
Vocational**	3 (0.6)	0 (0.0)	3 (0.6)
<i>Type of occupation***</i>			
Unemployed/Unstable	306 (64.3)	116 (24.4)	190 (39.9)
Blue-collar job	42 (8.8)	25 (5.3)	17 (3.6)
White-collar job	128 (26.9)	87 (18.3)	41 (8.6)
Missing	24	5	19
<i>Marital status</i>			
Single	278 (55.6)	103 (20.6)	175 (35.0)
Married	189 (37.8)	109 (21.8)	80 (16.0)
Cohabiting	27 (5.4)	15 (3.0)	12 (2.4)
Widowed	6 (1.2)	6 (1.2)	0 (0.0)
<i>Religion</i>			
Catholic	440 (89.8)	196 (40.0)	244 (49.8)
Protestant	11 (2.2)	8 (1.6)	3 (0.6)
Muslim	15 (3.1)	9 (1.8)	6 (1.2)
Others	24 (4.9)	13 (2.7)	11 (2.2)
Missing	10	7	3
<i>Socioeconomic status</i>			
Less than 90.91 USD (5,000 PHP)	250 (50.3)	96 (19.3)	154 (30.9)
90.91 USD to 363.62 USD (5,000 to 20,000 PHP)	159 (31.9)	71 (14.3)	88 (17.7)
Above 363.62 USD (20,000 PHP)	88 (17.7)	64 (12.9)	23 (4.8)

Missing	3	2	1
<b>LIFESTYLE FACTORS</b>			
<i>Use of contraceptive</i>			
No	338 (77.6)	168 (33.6)	220 (44.0)
Yes	112 (22.4)	65 (13.0)	47 (9.4)
<i>Smoking history</i>			
Never smoker	468 (93.8)	207 (41.5)	261 (52.3)
Ever smoker	31 (6.2)	25 (5.0)	6 (1.2)
Missing	1	1	0
<i>Alcohol use</i>			
Never alcoholic	412 (82.6)	170 (34.1)	242 (48.5)
Ever alcoholic	87 (17.4)	62 (12.4)	25 (5.0)
Missing	1	1	0
<i>Illicit drug use</i>			
No	496 (99.4)	230 (46.1)	266 (53.3)
Yes	3 (0.6)	2 (0.4)	1 (0.2)
Missing	1	1	0
<i>Immunized from at least one VPD</i>			
No	260 (64.4)	106 (26.2)	154 (38.1)
Yes	144 (35.6)	37 (9.2)	107 (26.5)
Missing	96	90	6
<i>History of at least one VPD</i>			
No	344 (69.8)	160 (32.5)	184 (37.3)
Yes	149 (30.2)	68 (13.8)	81 (16.4)
Missing	7	5	2
<i>Blood type</i>			
A	113 (24.1)	43 (9.2)	70 (14.9)
B	88 (18.8)	37 (7.9)	51 (10.9)
O	237 (50.5)	113 (24.1)	124 (26.4)
AB	31 (6.6)	15 (3.2)	16 (3.4)
Unrecalled	31	25	6
<i>Travel history</i>			
No	484 (96.8)	219 (43.8)	265 (53.0)
Yes	16 (3.2)	14 (2.8)	2 (0.4)
<b>OBSTETRIC-GYNECOLOGIC FACTORS</b>			
<i>Gravidity</i>			
Two at most	320 (64.1)	153 (30.7)	167 (33.5)
At least 3	179 (35.9)	79 (15.8)	100 (20.0)
Missing	1	1	0
<i>Parity</i>			
Two at most	376 (75.4)	161 (32.3)	215 (43.1)
At least 3	123 (24.6)	71 (14.2)	52 (10.4)
Missing	1	1	0
<b>COVID-19 EXPOSURE</b>			
Negative	267 (53.4)	120 (24.0)	147 (29.4)
Positive	233 (46.6)	113 (22.6)	120 (24.0)

\*Unless otherwise specified, all summary statistics are expressed in counts and percentage of the total,  $n$  (%).

\*\*Vocational education refers to the short-course for semi-skilled or skilled technical-vocational programs and certifications offered by the Technical Education and Skills Development Authority (TESDA).

\*\*\*As per the International Labor Organization, Blue-collar workers are those whose jobs are mostly unskilled, semi-skilled or skilled manual work in various trades, equipment operation, and maintenance. White-collar

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

workers are those whose jobs involve non-manual office, clerical, sales, semi-technical, professional, or supervisory activities<sup>27</sup>.

For peer review only

# Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
<b>Title and abstract</b>		
Title	<a href="#">#1a</a> Indicate the study's design with a commonly used term in the title or the abstract	1

1	Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and balanced summary	2
2				
3				
4			of what was done and what was found	
5				
6	<b>Introduction</b>			
7				
8				
9				
10	Background /	<a href="#">#2</a>	Explain the scientific background and rationale for the	3
11				
12	rationale		investigation being reported	
13				
14				
15	Objectives	<a href="#">#3</a>	State specific objectives, including any prespecified	4
16				
17			hypotheses	
18				
19				
20	<b>Methods</b>			
21				
22				
23				
24	Study design	<a href="#">#4</a>	Present key elements of study design early in the paper	4
25				
26				
27	Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant dates, including	4
28				
29			periods of recruitment, exposure, follow-up, and data collection	
30				
31				
32	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the sources and methods of	4
33				
34			selection of participants. Describe methods of follow-up.	
35				
36				
37	Eligibility criteria	<a href="#">#6b</a>	For matched studies, give matching criteria and number of	4
38				
39			exposed and unexposed	
40				
41				
42				
43	Variables	<a href="#">#7</a>	Clearly define all outcomes, exposures, predictors, potential	5
44				
45			confounders, and effect modifiers. Give diagnostic criteria, if	
46				
47			applicable	
48				
49				
50	Data sources /	<a href="#">#8</a>	For each variable of interest give sources of data and details of	5
51				
52	measurement		methods of assessment (measurement). Describe	
53				
54			comparability of assessment methods if there is more than one	
55				
56				
57				
58				
59				
60				

group. Give information separately for for exposed and unexposed groups if applicable.

1				
2				
3				
4				
5				
6	Bias	<a href="#">#9</a>	Describe any efforts to address potential sources of bias	4
7				
8				
9	Study size	<a href="#">#10</a>	Explain how the study size was arrived at	4
10				
11				
12	Quantitative	<a href="#">#11</a>	Explain how quantitative variables were handled in the	5
13	variables		analyses. If applicable, describe which groupings were chosen,	
14			and why	
15				
16				
17				
18				
19	Statistical	<a href="#">#12</a>	Describe all statistical methods, including those used to control	
20	methods	<a href="#">a</a>	for confounding	
21				
22				
23				
24				
25	5			
26				
27				
28	Statistical	<a href="#">#12</a>	Describe any methods used to examine subgroups and	N/A
29	methods	<a href="#">b</a>	interactions	
30				
31				
32				
33	Statistical	<a href="#">#12</a>	Explain how missing data were addressed	5
34	methods	<a href="#">c</a>		
35				
36				
37				
38	Statistical	<a href="#">#12</a>	If applicable, explain how loss to follow-up was addressed	5
39	methods	<a href="#">d</a>		
40				
41				
42				
43				
44	Statistical	<a href="#">#12</a>	Describe any sensitivity analyses	
45	methods	<a href="#">e</a>		
46				
47				
48				
49	N/A			
50				
51				
52	<b>Results</b>			
53				
54				
55				
56	Participants	<a href="#">#13</a>	Report numbers of individuals at each stage of study—eg	6
57		<a href="#">a</a>	numbers potentially eligible, examined for eligibility, confirmed	
58				
59				
60				

eligible, included in the study, completing follow-up, and analysed. Give information separately for for exposed and unexposed groups if applicable.

1			
2			
3			
4			
5			
6			
7			
8	Participants	<a href="#">#13</a>	Give reasons for non-participation at each stage
9			
10		<a href="#">b</a>	
11			
12			
13	Participants	<a href="#">#13</a>	Consider use of a flow diagram
14			
15		<a href="#">c</a>	
16			
17			
18	N/A		
19			
20			
21			
22	Descriptive data	<a href="#">#14</a>	Give characteristics of study participants (eg demographic,
23			
24		<a href="#">a</a>	clinical, social) and information on exposures and potential
25			
26			confounders. Give information separately for exposed and
27			
28			unexposed groups if applicable.
29			
30			
31			
32	Descriptive data	<a href="#">#14</a>	Indicate number of participants with missing data for each
33			
34		<a href="#">b</a>	variable of interest
35			
36			
37	6		
38			
39			
40	Descriptive data	<a href="#">#14</a>	Summarise follow-up time (eg, average and total amount)
41			
42		<a href="#">c</a>	
43			
44			
45	N/A		
46			
47			
48			
49	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures
50			
51			over time. Give information separately for exposed and
52			
53			unexposed groups if applicable.
54			
55			
56	7-9		
57			
58			
59			
60			

1	Main results	<a href="#">#16</a>	Give unadjusted estimates and, if applicable, confounder-	7-9		
2			a		adjusted estimates and their precision (eg, 95% confidence	
3					interval). Make clear which confounders were adjusted for and	
4						why they were included
5						
6						
7						
8						
9						
10	Main results	<a href="#">#16</a>		Report category boundaries when continuous variables were		
11			b	categorized		
12	Main results	<a href="#">#16</a>		If relevant, consider translating estimates of relative risk into		
13			c			absolute risk for a meaningful time period
14						
15						
16	Main results	<a href="#">#16</a>	If relevant, consider translating estimates of relative risk into			
17					c	absolute risk for a meaningful time period
18	N/A					
19					Other analyses	<a href="#">#17</a>
20	interactions, and sensitivity analyses					
21		Discussion				
22	Key results					<a href="#">#18</a>
23		Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into account sources of	11	
24	potential bias or imprecision. Discuss both direction and					
25						magnitude of any potential bias.
26						
27						
28						
29	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation considering objectives,	9-11		
30					limitations, multiplicity of analyses, results from similar studies,	
31						and other relevant evidence.
32						
33	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external validity) of the study	11		
34					results	
35	Other Information					
36						
37						
38						



1 Funding [#22](#) Give the source of funding and the role of the funders for the 12  
2  
3 present study and, if applicable, for the original study on which  
4  
5 the present article is based  
6  
7

8  
9 The STROBE checklist is distributed under the terms of the Creative Commons Attribution License  
10  
11 CC-BY. This checklist was completed on 27. November 2022 using <https://www.goodreports.org/>, a  
12  
13 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60